|
|
| [PMID]: | 28777197 |
| [Au] Autor: | Coquerel D; Chagnon F; Sainsily X; Dumont L; Murza A; Côté J; Dumaine R; Sarret P; Marsault É; Salvail D; Auger-Messier M; Lesur O |
| [Ad] Endereço: | 1Centre de Recherche du CHUS (CRCHUS) et Unité des Soins Intensifs Médicaux, Département de Médecine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. 2Institut de Pharmacologie de Sherbrooke (IPS) and Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. 3IPS Thérapeutique, Sherbrooke, QC, Canada. |
| [Ti] Título: | ELABELA Improves Cardio-Renal Outcome in Fatal Experimental Septic Shock. |
| [So] Source: | Crit Care Med;45(11):e1139-e1148, 2017 Nov. | | [Is] ISSN: | 1530-0293 |
| [Cp] País de publicação: | United States |
| [La] Idioma: | eng |
| [Ab] Resumo: | OBJECTIVES: Apelin-13 was recently proposed as an alternative to the recommended ß-adrenergic drugs for supporting endotoxin-induced myocardial dysfunction. Since Apelin-13 signals through its receptor (Apelin peptide jejunum) to exert singular inotropic/vasotropic actions and to optimize body fluid balance, this candidate pathway might benefit septic shock management. Whether the newly discovered ELABELA (ELA), a second endogenous ligand of the Apelin peptide jejunum receptor highly expressed in the kidney, further improves cardio-renal impairment remains unknown. DESIGN, SETTING, AND SUBJECTS: Interventional study in a rat model of septic shock (128 adult males) to assess the effects of ELA and Apelin-13 on vascular and cardio-renal function. Experiments were performed in a tertiary care University-based research institute. INTERVENTIONS: Polymicrobial sepsis-induced cardiac dysfunction was produced by cecal ligation puncture to assess hemodynamic efficacy, cardioprotection, and biomechanics under acute or continuous infusions of the apelinergic agonists ELA or Apelin-13 (39 and 15 µg/kg/hr, respectively) versus normal saline. MEASUREMENTS AND MAIN RESULTS: Apelinergic agonists improved 72-hour survival after sepsis induction, with ELA providing the best clinical outcome after 24 hours. Apelinergic agonist infusion counteracted cecal ligation puncture-induced myocardial dysfunction by improving left ventricular pressure-volume relationship. ELA-treated cecal ligation puncture rats were the only group to 1) display a significant improvement in left ventricular filling as shown by increased E-wave velocity and left ventricular end-diastolic volume, 2) exhibit a higher plasma volume, and 3) limit kidney injury and free-water clearance. These beneficial renal effects were superior to Apelin-13, likely because full-length ELA enabled a distinctive regulation of pituitary vasopressin release. CONCLUSIONS: Activation of the apelinergic system by exogenous ELA or Apelin-13 infusion improves cardiovascular function and survival after cecal ligation puncture-induced sepsis. However, ELA proved better than Apelin-13 by improving fluid homeostasis, cardiovascular hemodynamics recovery, and limiting kidney dysfunction in a vasopressinergic-dependent manner. |
| [Mh] Termos MeSH primário: |
Peptídeos e Proteínas de Sinalização Intercelular/farmacologia
Hormônios Peptídicos/farmacologia
Choque Séptico/tratamento farmacológico
|
| [Mh] Termos MeSH secundário: |
Animais
Biomarcadores
Citocinas/imunologia
Modelos Animais de Doenças
Ecocardiografia
Hemodinâmica/efeitos dos fármacos
Masculino
Ratos
Reação em Cadeia da Polimerase em Tempo Real
|
| [Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Biomarkers); 0 (Cytokines); 0 (ELA peptide, human); 0 (Intercellular Signaling Peptides and Proteins); 0 (Peptide Hormones); 0 (apelin-13 peptide) |
| [Em] Mês de entrada: | 1710 |
| [Cu] Atualização por classe: | 171025 |
[Lr] Data última revisão:
| 171025 |
| [Sb] Subgrupo de revista: | AIM; IM |
| [Da] Data de entrada para processamento: | 170805 |
| [St] Status: | MEDLINE |
| [do] DOI: | 10.1097/CCM.0000000000002639 |
| |
|
|
